The most recent projections suggest that the prevalence of heart failure with reduced
ejection fraction (HFrEF) will dramatically expand as the United States’ population
ages.
1
Two decades have past since the benefit of the original pillars of guideline-directed
medical therapy (GDMT), beta-blockers (BBs) and renin angiotensin system inhibitors
(RASis) was first established in patients with HFrEF. Since then, the supportive data
and armamentarium of therapies have only grown.
2
,
3
,
4
,
5
,
6
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Cardiac FailureAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Heart Disease and Stroke Statistics-2023 Update: a report from the American Heart Association.Circulation. 2023;
- Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.Lancet. 2001; 357: 1385-1390
- Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study.Circulation. 2002; 106: 2194-2199
- and the MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF).Lancet. 1999; 353: 2001-2007
- Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT).Circulation. 2002; 106: 2454-2458
- Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.N Engl J Med. 1992; 327: 685-691
- Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF Registry.J Am Coll Cardiol. 2018; 72: 351-366
- Use of evidence-based therapy in heart failure with reduced ejection fraction across age strata.Eur J Heart Fail. 2022; 24: 1047-1062
- Multimorbidity in older adults with cardiovascular disease.J Am Coll Cardiol. 2018; 71: 2149-2161
- Deprescribing in older adults with cardiovascular disease.J Am Coll Cardiol. 2019; 73: 2584-2595
- Frailty in cardiology: definition, assessment and clinical implications for general cardiology. A consensus document of the Council for Cardiology Practice (CCP), Association for Acute Cardio Vascular Care (ACVC), Association of Cardiovascular Nursing and Allied Professions (ACNAP), European Association of Preventive Cardiology (EAPC), European Heart Rhythm Association (EHRA), Council on Valvular Heart Diseases (VHD), Council on Hypertension (CHT), Council of Cardio-Oncology (CCO), Working Group (WG) Aorta and Peripheral Vascular Diseases, WG e-Cardiology, WG Thrombosis, of the European Society of Cardiology, European Primary Care Cardiology Society (EPCCS).Eur J Prev Cardiol. 2022; 29: 216-227
- Enrollment of older patients, women, and racial and ethnic minorities in contemporary heart failure clinical trials: a systematic review.JAMA Cardiol. 2018; 3: 1011-1019
- B-type natriuretic peptide during treatment with sacubitril/valsartan: the PARADIGM-HF Trial.J Am Coll Cardiol. 2019; 73: 1264-1272
- Medicare coverage and out-of-pocket costs of quadruple drug therapy for heart failure.J Am Coll Cardiol. 2022; 79: 2516-2525
- Electronic alerts to improve heart failure therapy in outpatient practice: a cluster randomized trial.J Am Coll Cardiol. 2022; 79: 2203-2213
Article info
Publication history
Published online: February 23, 2023
Accepted:
February 16,
2023
Received:
February 16,
2023
Publication stage
In Press Journal Pre-ProofFootnotes
New Haven, Connecticut
Identification
Copyright
© 2023 Elsevier Inc. All rights reserved.
